Brian McVeigh, Code Bio CEO

Take­da signs off on a $2B deal aimed at by­pass­ing AAV road­blocks on the way to gene ther­a­py 2.0

Take­da has tak­en an­oth­er step down the road to build­ing up its gene ther­a­py plat­form.

The phar­ma gi­ant an­nounced Tues­day morn­ing that it’s struck the lat­est in a se­ries of deals with one of the up­starts in the field to ex­plore new de­signs for de­liv­ery ve­hi­cles — look­ing to go far past the AAV pro­to­types that have dri­ven the field so far.

The spot­light to­day falls on Code Bio­ther­a­peu­tics, a pri­vate start­up run by ex-GSK BD chief Bri­an McVeigh.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.